Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy Sells 920 Shares

Natera, Inc. (NASDAQ:NTRA - Get Free Report) CFO Michael Burkes Brophy sold 920 shares of the company's stock in a transaction on Tuesday, July 22nd. The stock was sold at an average price of $139.58, for a total value of $128,413.60. Following the sale, the chief financial officer owned 70,494 shares of the company's stock, valued at $9,839,552.52. The trade was a 1.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Michael Burkes Brophy also recently made the following trade(s):

• On Thursday, July 24th, Michael Burkes Brophy sold 755 shares of Natera stock. The stock was sold at an average price of $139.50, for a total value of $105,322.50.
• On Wednesday, July 23rd, Michael Burkes Brophy sold 495 shares of Natera stock. The stock was sold at an average price of $141.28, for a total value of $69,933.60.
• On Monday, July 21st, Michael Burkes Brophy sold 602 shares of Natera stock. The stock was sold at an average price of $139.29, for a total transaction of $83,852.58.
• On Monday, April 28th, Michael Burkes Brophy sold 2,018 shares of Natera stock. The stock was sold at an average price of $152.18, for a total transaction of $307,099.24.

Natera Price Performance

Shares of NTRA stock traded up $3.25 on Thursday, reaching $141.07. 1,421,449 shares of the company were exchanged, compared to its average volume of 1,212,550. The company has a market cap of $19.26 billion, a price-to-earnings ratio of -95.97 and a beta of 1.73. The company has a 50-day moving average of $159.07 and a 200-day moving average of $157.34. Natera, Inc. has a one year low of $92.14 and a one year high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The medical research company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.59) by $0.09. Natera had a negative net margin of 10.36% and a negative return on equity of 18.29%. The company had revenue of $501.83 million for the quarter, compared to analysts' expectations of $446.68 million. During the same quarter in the prior year, the firm earned ($0.56) EPS. The business's revenue was up 36.5% on a year-over-year basis. As a group, sell-side analysts predict that Natera, Inc. will post -1.49 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have recently issued reports on NTRA. UBS Group upped their price target on shares of Natera from $211.00 to $218.00 and gave the stock a "buy" rating in a report on Friday, May 9th. Barclays upped their price target on shares of Natera from $160.00 to $190.00 and gave the stock an "overweight" rating in a report on Friday, May 9th. Wall Street Zen downgraded Natera from a "hold" rating to a "sell" rating in a report on Saturday, May 17th. Finally, Piper Sandler increased their price objective on Natera from $205.00 to $210.00 and gave the company an "overweight" rating in a report on Thursday, May 15th. One research analyst has rated the stock with a sell rating and fifteen have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $184.63.

Hedge Funds Weigh In On Natera

Several large investors have recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD increased its stake in Natera by 134.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,742,428 shares of the medical research company's stock valued at $1,067,327,000 after buying an additional 3,871,862 shares during the last quarter. JPMorgan Chase & Co. increased its stake in Natera by 43.7% in the 4th quarter. JPMorgan Chase & Co. now owns 6,701,425 shares of the medical research company's stock valued at $1,060,836,000 after buying an additional 2,036,396 shares during the last quarter. Norges Bank purchased a new stake in Natera in the 4th quarter valued at about $224,040,000. Vanguard Group Inc. increased its stake in Natera by 7.7% in the 4th quarter. Vanguard Group Inc. now owns 12,316,470 shares of the medical research company's stock valued at $1,949,697,000 after buying an additional 879,463 shares during the last quarter. Finally, Nuveen LLC purchased a new stake in Natera in the 1st quarter valued at about $113,375,000. Institutional investors own 99.90% of the company's stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.